Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | ELOC | Q15369 | 1/20 | 0.33 |
| ▸ | ELOB | Q15370 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973994 | 0.85 | DGAT1 (0.36) | VHLELOCELOBNOTUMCES2 | |
| SCHEMBL19973951 | 0.84 | ALDH1A1 (0.38) | ALDH1A1ALOX15NOTUMCES2CES1 | |
| SCHEMBL28914080 | 0.81 | ALDH1A1 (0.31) | ALDH1A1CES2 | |
| SCHEMBL14053008 | 0.80 | VHL (0.37) | VHLELOCELOBNOTUM | |
| SCHEMBL21189321 | 0.72 | VHL (0.38) | ALDH1A1ALOX15VHLELOCELOB | |
| SCHEMBL5450432 | 0.67 | ABL1 (0.37) | ALDH1A1 | |
| SCHEMBL8308598 | 0.67 | ALDH1A1 (0.36) | ALDH1A1ALOX15CES2CES1 | |
| SCHEMBL8136278 | 0.65 | KDM4E (0.34) | ALDH1A1NOTUM | |
| SCHEMBL8346491 | 0.63 | VHL (0.41) | ALDH1A1VHLELOCELOBCES1 | |
| SCHEMBL7840446 | 0.63 | BRD4 (0.34) | ALDH1A1VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | ALDH1A1 3241/4885ALOX15 4718/4885VHL 164/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | ALDH1A1 3241/4885ALOX15 4718/4885VHL 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.